Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BTTR $7 in some $6s 300k floater and lawsuit go well together for a potential scalp.. $6.10 support stop loss 6.62 - 6.72 next minor support. Also will eventually need volume
NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, initiated a legal action to enforce a right of first refusal (“ROFR”) option exercised by Alphia, Inc. (“Alphia”) BL4424547, which is controlled by a Paris-based private equity firm, PAI Partners (https://www.paipartners.com). Pursuant to the terms of a written agreement between Alphia and the Company, Alphia is obligated to acquire the assets of Halo, Purely for Pets, Inc., a wholly owned subsidiary of Better Choice. Better Choice seeks to compel the closing of the asset sale and, in the alternative, monetary damages in excess of $19 million caused by Alphia for its misconduct in connection with the ROFR. “After several unsuccessful attempts to communicate with both Winston Song of PAI Partners and David McLain, the CEO of Alphia, and given the significant burden imposed upon Better Choice by Alphia’s refusal to close the transaction, Better Choice had no viable option other than to pursue legal action to enforce the terms of the ROFR, as well as all of its rights,” stated Better Choice Chairman, Michael Young. The claim has been filed in the Circuit Court of the 13th Judicial Circuit in and for Hillsborough County, Florida.
About Better Choice Company, Inc.
PXMD HNRA 2.50s resistance for HNRA 2.61- 2.96 then a $3 breaks sees $3.40
PXMD stay above 1.09 for the 4hr and 1.70s next
ALLR 3.84
ALLR 3.62
ALLR 3.49 200k float ..round 2 start cashing some chips again
ALLR 2.60s round 2 ready
TMF hit $48 can flip some $46s here and wait for the dip again or just hold em
CISS 1.99 wait until end of day for cheapies reverse split completed
PXMD NXPL BENF ALLR HUBC ZPTA TPET HKD VIAO MI
Paxmedica IncPXMD
1.15 +177.11% 31.86M
Nextplat CorpNXPL
2.47 +63.58% 18.84M
BeneficientBENF
0.11 +64.98% 53.31M
Allarity Therapeut.ALLR
2.83 +23.00% 3.9M
Hub Cyber SecurityHUBC
1.44 +23.08% 4.1M
Zapata Computing H.ZPTA
3.10 +24.00% 7.1M
Trio PetroleumTPET
0.2944 +24.75% 19.24M
AMTD DigitalHKD
3.91 +23.34% 872.63K
Via Optronics AgVIAO
0.56 +21.74% 45.94K
Nft LtdMI
5.85 +3,934.48% 6.69K
GDXU nice $42 out of some more next levels to watch 43.17 and 46.36.
After China CPI PPI report TMF should hold support at $46 for entry
NRXP 6.77 + 22% break 7.01 then 8.90 up next 6m
Float .. There are medicines available to help manage the highs and lows of bipolar disorder, but not a single-dose treatment. Typically, it requires one to manage mania and another for depression. They may not work for everyone and come with their own set of side effects.
Modifying The NMDA Receptor
NRx Pharmaceuticals Inc.
, a clinical-stage biopharmaceutical company, believes it has the answer with NRX-101. It's the biopharmaceutical company's FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. The company is targeting life-threatening diseases that often go untreated with NRX-101, which is a patented, oral fixed-dose combination of two FDA-approved drugs: D-cycloserine, an NMDA receptor modulator at certain dosage ranges; and Lurasidone, a 5-HT2a receptor antagonist.
Combined, the drugs target the NMDA receptor which is critical for memory function and the formation of new thoughts in the brain. At excessive rates of NMDA activity, ideas including the creation of new ones are slowed down. People with bipolar disorder tend to ruminate on fewer and more negative thoughts in that state. When the NMDA channel is blocked, thoughts can flow rapidly and incoherently, leading to hallucinations and psychosis. The challenge is to strike a healthy balance between the two. By modulating the NMDA, NRx believes it can improve the function of the thought-forming cells in the brain and thus reduce suicidal ideation. If approved by the U.S. Food and Drug Administration (FDA) and other health regulatory agencies, the company says it would be the first medicine regimen targeted to treat severe bipolar depression in patients with both acute and sub-acute suicidal ideation or behavior (ASIB and SSIB).
Trial Over-Enrolled
The company is taking steps to make that a reality, recently completing enrollment of a phase 2b/3 study of NRX-101 for 74 patients suffering from bipolar disorder. Enrollment exceeded the original target of 70 patients, to enhance the statistical power of the study, NRx said. Top-line data is expected later this month.
“To our knowledge, NRX-101 is the first and only oral medication to have demonstrated reduced suicidal ideation in patients with bipolar depression," said Dr. Jonathan Javitt, Founder, Chairman and Chief Scientist of NRx Pharmaceuticals. "On the basis of our previous trial, it was awarded Breakthrough Therapy Designation by the FDA and we aim to confirm its effect on depression and suicidal ideation in this trial."
NRX teamed up with Alvogen Pharmaceuticals for the development and marketing of the combined therapy. During its fourth quarter, NRx said Alvogen advanced its first $5.1 million milestone payment. A successful readout from the phase 2b trial and FDA interaction will trigger an additional $4 million milestone payment together with the transfer of future development costs to Alvogen. The partnership provides for potential milestones of $329 million and a royalty reaching 15% on net sales, according to NRx.
Beyond Bipolar Disorder
It's not just bipolar disorder that NRx is aiming to treat with its NMDA therapy platform. The company is making inroads in using its lead compound in chronic pain, betting results of a 200-person efficacy trial conducted by Northwestern University could create a multibillion-dollar opportunity for NRx. Chronic pain is another condition that plagues more than 50 million Americans in which the available treatments have mixed results.
Then there's its new drug application for IV ketamine in acute suicidality. NRx said it is building a specialty pharmaceutical business around ketamine it expects to yield positive cash flow by the end of 2024. Called HOPE Therapeutics, NRx plans to submit a new drug application with the FDA this year. In advance of FDA approval, HOPE partnered with national 503b and 503a pharmacies to address the ketamine shortage reported by the FDA since 2018. The goal is to spin HOPE out into a stand-alone company owned by NRx, current NRx shareholders via a tax-free dividend and new investors. NRx said prospective anchor investors offered $60 million in new investment dollars once HOPE is publicly listed. NRx said HOPE is presenting data from four randomized, prospective trials demonstrating safety and efficacy in 800 patients as the clinical basis for its new drug application (NDA) for HTX-100 (IV Ketamine).
And if that's not enough, NRx recently received Qualified Infectious Disease Product (QIDP) and Fast Track designation from the FDA for NRX-101 in the treatment of complicated urinary tract infections (cUTI) and pyelonephritis. It’s a condition the company says affects 3 million people in the U.S. resulting in over 15,000 deaths annually. NRx is currently seeking partners with active involvement in urology, infectious disease and/or women’s health for commercialization of NRX-101.
“2023 was a pivotal year for NRx in which we advanced from a single clinical trial in a single indication to a dramatically streamlining operation with a 50% reduction in overhead costs, a 25% reduction in overall costs and a $0.20 per share improvement in negative earnings, while completing our clinical trial objectives," says Stephen Willard, J.D., Chief Executive Officer and Director of NRx Pharmaceuticals. ‘We expect data from two key trials this month and predict our first commercial revenue by the end of 2024."
ZPTA NXPL OCX HKD NRXP LYEL GL NEXT IINN XXII LGVN RR GDXU
ALLR $4.06 hit that 200k float
MI 1 to 50 reverse split .80
Hit it 200k float
China CPI fell by 1% about the most in 20 years and PPI was down 0.01% for 5th month in a row …so will the Fed do a rate cut sooner then later ..probably..
China largest importer of crude oil saw imports drop as industrial production dropped so this is disinflationary
CNY down = BAD News for World
Yes you did alert PXMD
PXMD nice one 1.09 resistance
Economy is robust lol with car dealerships new and used closing down at record paces 2008 reenactment and car repos running at 50,000 per day. Banks won’t lend and finance to cats and dogs nor should they have been allowed but government allowed it..
Housing markets in Texas Austin so many listings it’s a buyers markets 35,000 to 131,000 sellers sitting with unsold properties
Ride it saddle up $7s CADL…Co announced that the FDA has granted Orphan Drug Designation to CAN-2409, Candel's most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer.
NVDA boom boom Nasdaq anything NVDA related will follow soon enough.. dips dips.
All that matters is the weekly 5ema on SPX which has held every week miraculously PPT plunge protection team since November and tomorrow Friday …lol 401k day.
Rally rally lol
Well you’re fine on HYMC sit back and have some AMC popcorn now and see how the movie plays out. Was another moon market pick you were in
RELL once it breaks 10.77 and establishes support at this zone will start going …but One step at a time
HYMC look for 4.81 low floater break then 5.01- 5.47 becomes interesting. Doesn’t AMC own a good chunk of this probably there bread and butter would think for popcorn man lol
AMC Entertainment Holdings Inc. Announces Significant Investment, Buying 22% of Hycroft Mining Holding Corporation
AMC buying 22% of Hycroft Mining Holding Corporation, and to receive an additional 23.4 million warrants in Hycroft at $1.07 per share
Making an investment equal to AMC is Eric Sprott, one of the world’s leading gold and silver investors
The 71,000 acre Hycroft Mine in northern Nevada is one of North America’s largest development sites
Independent third-party studies confirm that the Hycroft Mine has some 15 million ounces of gold resources and some 600 million ounces of silver resources
With its investment, AMC has been granted the right to appoint a representative to the Hycroft Board of Directors
CORRECTION...by Business Wire
March 15, 2022 07:11 AM Eastern Daylight Time
MNPR .80 HYMC 4.22 ascending now
RELL 10.40 resistance level then 10.60-.68 then 10.88- 11.67 would be a bigger breakout zone
A little something to SING .26 about
44.80- 46.20 TMF zone to watch DRV scale out more at 42.76 next zone further up at $49 hold house gains for longer term
HNRA $2.44s next oil gas low floater after TPET took some dibs
ALLR 3.03 even better 200k floater market cap under 1m . Longer term hold but the dippities
ALLR 3.13 better entry point after reverse split 52 week low
Saddle up with CADL $6s +
26%
.28s premarket TPET for early risers to exit WEBULL MOO MOO
Dip some toes $1.64. Warrants at $2.43 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share (or common stock equivalent in lieu thereof) and accompanying warrant. The warrants have an exercise price of $2.43 per share, are exercisable immediately upon issuance and will expire five years after the date of issuance.
Dip a toe on some .70s warrants at 1.60
. The public offering price per share of Common Stock is $1.60 (or $1.5999 for each Pre-Funded Warrant, which is equal to the public offering price per share of Common Stock to be sold in the offering minus an exercise price of $0.0001 per Pre-Funded Warrant). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. The Common Warrants are exercisable immediately subject to registration and expire 5 years after the initial issuance date. The Company expects to use the net proceeds from the offering to help fund recent large orders within the Smart Building Technologies division from customers including: Siemens, Sherwin Williams and Arco Murray and other general corporate purposes.
Aegis Capital Corp. acted as the exclusive placement agent for the offerings. Sichenzia Ross Ference Carmel LLP acted as counsel to the Company for the offerings. Kaufman & Canoles, P.C. acted as counsel to the Placement Agent for the offerings.
RLYB RENT TPET VERB SPRC TC ALPN HNRA
Rallybio CorpRLYB
2.88 +1.25 +76.69% 6.7M 06:07:53
Trio PetroleumTPET
0.237 +0.0522 +28.25% 5.81M 06:04:46
VERB TECHVERB
0.2153 +0.0333 +18.30% 4.65M 06:01:29
C3is IncCISS
0.033 +0.0001 +0.30% 770.2K 05:57:03
Nikola CorpNKLA
0.93 -0.05 -4.64% 554.38K 05:52:44
Scisparc LtdSPRC
1.82 +0.140000 +8.33% 517.86K 06:07:00
Jaguar Health IncJAGX
0.1164 +0.0004 +0.34% 420.52K 05:55:29
Selina HospitalitySLNA
0.0762 0.0000 0.00% 365.64K 05:46:17
TuanChe ADRTC
2.14 +0.3400 +18.89% 332.31K 06:06:31
SINTX TechnologiesSINT
0.0251 +0.0003 +1.21% 0 05:28:27
Rallybio CorpRLYB
2.88 +76.69% 6.7M
Rent the RunwayRENT
10.31 +39.32% 122.27K
Alpine Immune Scie.ALPN
64.04 +36.14% 54.61K
Trio PetroleumTPET
0.237 +28.25% 5.81M
Chijet MotorCJET
0.47 +28.11% 0
HNR AcquisitionHNRA
2.98 +26.27% 0
Complete SolariaCSLR
0.62 +21.92% 0
Travere Therapeuti.TVTX
8.09 +21.29% 0
TuanChe ADRTC
2.14 +18.89% 332.31K
VERB TECHVERB
0.2153 +18.30% 4.65M
Dealerships are scared why so many going out of business…
https://www.youtube.com/@LuckyLopez777
Start looking for Bitcoin related dips BMR should be fine longer term.. SAI BTM SLNH BTBT HUT ELWS MARA RIOT CAN HIVE BTCM BTDR BTCS
MATH CLSK WULF IREN ANY BITF ARBK HUT MIGI GREE BTBT MARA RIOT SOS SDIG COIN NUKK CGA OCTO CIFR LMFA BRRR t
TPET out at .23
TMF 47.10 holds support add a few $47s if it doesn’t then wait for $44.80. Looks like $47 should hold but if doesn’t 44.80 will be better for DRV higher rates for mortgages